Navigation Links
Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
Date:12/7/2010

PARIS, Dec. 7, 2010 /PRNewswire/ -- Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), today announced that it has signed a non-exclusive agreement with Evrogen (Moscow, Russia) for access to its fluorescent proteins. This license allows Cellectis bioresearch to incorporate these proteins into its own products and will expand the company's offering of genome engineering tools.

Luc Selig, Sales and Marketing Director of Cellectis bioresearch, commented, "One of the key components of our kits is the integration matrix which enables the user to express a gene of interest. By extending the choice of promoters and tags in these matrices, we can offer our clients a full range of methods to achieve single-phase developments, thus saving valuable time during experiments."

Cellectis bioresearch develops and commercializes ready- and easy-to-use tools and technologies for the life science industry. These tools can be used to customize any cell for drug development, protein production or functional genomics. To date, Cellectis bioresearch markets over one hundred products through its online store and international distribution network and sales forces.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The kits can be purchased online from www.cellectis-bioresearch.com. Check the website for more information.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at www.cellectis.com.

Follow Cellectis on Twitter at www.twitter.com/cellectis.

About Evrogen

Evrogen is an innovation-driven company founded by scientists and dedicated to making successful ideas widely available as efficient products and services for life science research.

More information at www.evrogen.com.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
2. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
3. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
4. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
5. Cellectis Unveils Its New Corporate Website
6. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
7. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
8. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
9. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
10. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
11. Vet-Stem Signs License Agreement With Affiliate in Australia for Veterinary Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 MedGenome,s Commitment Will ... Understanding of Complex Diseases Such as Cancer, Metabolic ... --> --> MedGenome, the ... a leading provider of genomics research services globally, ... the GenomeAsia 100K consortium as a founding member. ...
(Date:2/11/2016)... -- Bioethics International, a not-for-profit organization focused on the ethics and ... accessible to patients around the world, today announced that the ... of the Good Pharma Scorecard an ,Editors, ... one of BMJ Open ,s ,Most Popular Articles, which ... frequently read. Ed Sucksmith , assistant editor of ...
(Date:2/11/2016)... 2016 --> ... (OTCQB: PSID), a life sciences company focused on ... subsidiary, which markets the Caregiver® FDA-cleared non-contact thermometer, ... January 2016, including entering into agreements with five ... growth, and establishing several near-term pipeline opportunities. ...
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... pleased to announce that Mitsui & Co. Ltd., its ... succinic acid plant, is investing an additional CDN$25 million ... increasing its stake from 30% to 40%.  Mitsui will ... bio-succinic acid produced in Sarnia , ...
Breaking Biology Technology:
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
Breaking Biology News(10 mins):